HAE vs. MMSI, ICUI, INSP, GKOS, STVN, AXNX, PRCT, IRTC, TNDM, and NARI
Should you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include Merit Medical Systems (MMSI), ICU Medical (ICUI), Inspire Medical Systems (INSP), Glaukos (GKOS), Stevanato Group (STVN), Axonics (AXNX), PROCEPT BioRobotics (PRCT), iRhythm Technologies (IRTC), Tandem Diabetes Care (TNDM), and Inari Medical (NARI). These companies are all part of the "surgical & medical instruments" industry.
Haemonetics (NYSE:HAE) and Merit Medical Systems (NASDAQ:MMSI) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.
Merit Medical Systems received 29 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 68.90% of users gave Merit Medical Systems an outperform vote while only 60.89% of users gave Haemonetics an outperform vote.
Haemonetics has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Comparatively, Merit Medical Systems has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
In the previous week, Haemonetics had 10 more articles in the media than Merit Medical Systems. MarketBeat recorded 19 mentions for Haemonetics and 9 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 1.01 beat Haemonetics' score of 0.51 indicating that Merit Medical Systems is being referred to more favorably in the news media.
Haemonetics presently has a consensus price target of $108.67, suggesting a potential upside of 13.51%. Merit Medical Systems has a consensus price target of $92.78, suggesting a potential upside of 13.30%. Given Haemonetics' higher possible upside, equities analysts plainly believe Haemonetics is more favorable than Merit Medical Systems.
Haemonetics has higher revenue and earnings than Merit Medical Systems. Haemonetics is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.
99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are owned by institutional investors. 1.8% of Haemonetics shares are owned by insiders. Comparatively, 3.7% of Merit Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Haemonetics has a net margin of 8.98% compared to Merit Medical Systems' net margin of 7.94%. Haemonetics' return on equity of 22.25% beat Merit Medical Systems' return on equity.
Summary
Haemonetics and Merit Medical Systems tied by winning 9 of the 18 factors compared between the two stocks.
Get Haemonetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Haemonetics Competitors List
Related Companies and Tools
